Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

32.84 +0.64 (+1.99%)
Streaming Delayed Price Updated: 12:38 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 Next >
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q1 2025 Financial Results on May 12, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at Stifel 2025 Virtual CNS Forum
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Outlines Key Corporate Milestone Opportunities for 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Reports Q3 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q3 2024 Financial Results on November 12, 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Reports Q2 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q2 2024 Financial Results on August 8, 2024
Conference Call and webcast scheduled at 4:30 pm ET 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.